KDR and cancer: While previous studies using VEGF-VEGFR2 based cancer therapies do not demonstrate reduction of cancer recurrence, targeting both VEGFR2 and S1PR1 have resulted in successful reduction in cancer and cancer recurrence (Balaji Ragunathrao et al., 2019).